Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612167 | 1.00 | TSHR (0.38) | TSHRALDH1A1CYP3A4ADH1BADH1C | |
| SCHEMBL12574999 | 0.97 | TSHR (0.36) | TSHRALDH1A1CYP3A4 | |
| Butane SCHEMBL28139255 | 0.94 | TSHR (0.40) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL7776902 | 0.91 | ANPEP (0.38) | TSHRALDH1A1CYP3A4ADH1BADH1C | |
| SCHEMBL18760750 | 0.88 | ALDH1A1 (0.48) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL4915543 | 0.87 | TSHR (0.30) | TSHR | |
| SCHEMBL4149586 | 0.87 | — | — | |
| SCHEMBL13995757 | 0.86 | ALDH1A1 (0.31) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL18177692 | 0.86 | KDM4E (0.39) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL19594655 | 0.86 | ALDH1A1 (0.31) | TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117205-A1 | BICYCLIC PYRIDINE DERIVATIVE AND SALT THEREOF, AND HARMFUL ORGANISM CONTROL AGENT CHARACTERIZED BY CONTAINING SAID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 北興化学工業株式会社 | 2024-06-06 | — | — | WO | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-20230331662-A1 | AN N,N-DIHYDROCARBONYLAMIDE CARBOXYLIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Golden Dragon Rare-Earth Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331662-A1 | AN N,N-DIHYDROCARBONYLAMIDE CARBOXYLIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Golden Dragon Rare-Earth Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| EP-4155291-A1 | N,N-DIHYDROCARBYL AMIDE CARBOXYLIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Changting Golden Dragon Rare-Earth Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-11548984-B2 | Light- or heat-curing method and curable resin composition | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2022266919-A1 | N,N-DIHYDROCARBYL AMIDE CARBOXYLIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | 福建省长汀金龙稀土有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| US-4077859-A | Polyunsaturated halogenated monomers for use in ultraviolet coating systems | CELANESE CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4077858-A | Completely polymerized ultraviolet cured coatings | CELANESE CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4060522-A | ANTICORROSIVE | BASF AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4042476-A | TITANIUM DIOXIDE-ACRYLIC POLYMER EMULSION | CELANESE CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
| US-4035321-A | Preparation of ultraviolet curable acrylated polymers | CELANESE CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-4016334-A | Method of applying high adhesion ultraviolet curable coatings and coated articles | CELANESE CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
| US-4008293-A | ACRYLIC COPOLYMER, AMINOPLAST, BINDER | PPG INDUSTRIES, INC. (US) | 1977-02-15 | — | — | US | disclosed |
| US-3992276-A | Unsaturated polyesters for ultraviolet curable coatings | CELANESE CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3992275-A | Low gloss ultraviolet curable coatings utilizing α,α,α-trichlorotoluene as a photoinitiator | CELANESE CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3988297-A | Process for the preparation of polyphenylene ethers with activated copper-amine catalysts | GENERAL ELECTRIC (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885CYP3A4 1389/4885 |
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | TSHR 3422/4885ALDH1A1 1981/4885CYP3A4 247/4885 |
| US-20230331662-A1 | AN N,N-DIHYDROCARBONYLAMIDE CARBOXYLIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | NOTUM, HADH, SLC39A11 | TSHR 3336/4885ALDH1A1 1024/4885CYP3A4 3203/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885CYP3A4 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.